Share this

Non-PCV Serotypes

A PROPORTION OF ADULT IPD CASES ARE CAUSED BY NON-PCV SEROTYPES1,3,a

Each serotype causes a different number of adult IPD cases.4 Some serotypes cause more cases of adult IPD than others.1,3

~1 IN 3 CASES

of IPD in adults aged ≥65 years
is due to serotypes not included in current PCVs.5-7,a,b

ADULT IPD EPIDEMIOLOGY HAS CHANGED

Over the last decade, the serotypes that have caused the majority of IPD cases in adults aged ≥65 years have shifted.5

IPD, invasive pneumococcal disease;=PCV, pneumococcal conjugate vaccine.
a PCVs include serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F.6,7
b Based on European Centre for Disease Prevention and Control data for adults aged ≥65 in Europe and may not reflect local pneumococcal disease epidemiology in the UAE. Regional variations may exist.5

NEARLY HALF
(~44%)8,b

of all IPD cases in adults 50+ in
USA are caused by serotypes not
included in any other PCV
approved for adults.2,9,a

ADULT IPD EPIDEMIOLOGY HAS CHANGED

Over the last decade, the serotypes that have caused the majority of IPD cases in adults aged ≥65 years have shifted.5

IPD, invasive pneumococcal disease;=PCV, pneumococcal conjugate vaccine.
a PCVs include serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, 33F.6,7
b Based on CDC ABC surveillance data from the years 2018-2022 and may not reflect local pneumococcal disease epidemiology in the UAE. Regional variations may exist.9

References

  1. Grant, L. R., Slack, M. P. E., Theilacker, C., et al. (2023). Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies. Vaccine, 41(38), 5662–5669.
  2. Centers for Disease Control and Prevention. (2024). ABCs bact facts interactive data dashboard: SPN serotypes 1998–2023. Accessed 26 September 2025. https://www.cdc.gov/abcs/bact-facts/data-dashboard.html.
  3. Grant, L. R., Meche, A., McGrath, L., et al. (2023). Supplementary material to Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies. Vaccine, 41(38), 5662–5669.
  4. Gierke, R., Wodi, A. P., & Kobayashi, M. (2024). Pneumococcal disease. In Epidemiology and prevention of vaccine-preventable diseases (14th ed., Chap. 17). Centers for Disease Control and Prevention. Accessed 26 September 2025. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-17-pneumococcal-disease.html.
  5. European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases. Invasive pneumococcal disease. Accessed 26 September 2025. https://atlas.ecdc.europa.eu/public/index.aspx.
  6. Prevenar 20 SmPC.
  7. Prevenar 13 SmPC.
  8. Kobayashi, M., Leidner, A. J., Gierke, R.,et al. (2025) Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged ≥50 years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024. Morbidity and Mortality Weekly Report, 74(1), 1–9.
  9. Centers for Disease Control and Prevention. (2025). 1998–2023 serotype data for invasive pneumococcal disease cases by age group from Active Bacterial Core surveillance: Ages 18–49, 50–64, 65+. Accessed 26 September 2025. https://data.cdc.gov/Public-Health-Surveillance/1998-2023-Serotype-Data-for-Invasive-Pneumococcal-/qvzb-qs6p/data_preview.

AE-NON-00601 | Expiry Date: 26/09/2027